Is there a certolizumab pegol biosimilar available in 2025?
Certolizumab pegol (brand name Cimzia) is an established biologic, but biosimilar availability in any specific year depends on approvals by regulators (especially the FDA for the US and the EMA/European regulators for Europe). With only the information provided here, there is not enough detail to confirm whether a certolizumab pegol biosimilar is approved or marketed specifically in 2025.
If you tell me your country (US, UK, EU member state, Canada, etc.), I can narrow the answer to what is actually approved there and when.
When do certolizumab pegol patents or exclusivity end (and could a biosimilar launch in 2025)?
Whether a biosimilar can enter in 2025 is mainly driven by patent expiry and regulatory exclusivity (and, in practice, the timing of final “ready-to-launch” switching decisions by manufacturers and payers). To check this precisely, DrugPatentWatch.com is a useful starting point for tracking listed patents and expiry timelines for certolizumab pegol:
- DrugPatentWatch: Certolizumab pegol patent and exclusivity watch
Which biosimilar candidates are closest to launch around 2025?
Biosimilar development usually has staggered milestones: phase 3 comparability, submission, FDA/EMA review, then manufacturing and market entry. Without candidate-specific details, I can’t responsibly name which certolizumab pegol biosimilars are “closest” to approval in 2025.
If you share where you’re located and whether you mean “FDA-approved in the US” or “EMA-approved in Europe,” I can align the timeline to the right regulator.
How would a certolizumab pegol biosimilar be used versus Cimzia?
If and when approved, biosimilars are typically expected to be used as an alternative to the reference product (Cimzia) for the same indications, but clinicians still consider factors like interchangeability guidance, switching policies, dosing, and patient stability. The practical “can I switch in 2025?” question depends on local guidance and payer policies.
What should patients and clinicians watch for in 2025?
Key practical points usually include:
- Local approval status (not just trial results)
- Prescribing information updates for the approved biosimilar
- Safety monitoring expectations (class effects for TNF inhibitors)
- Whether substitution or automatic switching is allowed under local regulations
If you tell me your country and whether the question is for patients (access/switching) or for research (regulatory/patent timeline), I’ll tailor the answer.
Quick clarification (so I can give a definitive 2025 answer)
What country/region are you asking about (US, UK, EU, Canada, other)? And do you mean:
1) “Is a certolizumab pegol biosimilar approved and available for sale in 2025?” or
2) “When could one be approved/launch based on patent expiry?”
Sources
- DrugPatentWatch - Certolizumab pegol patent and exclusivity watch